Noncontraceptive Benefits of 17β-Estradiol COCs During Adolescence

Adolescent sexuality and reproductive health care is a discussion topic with issues related to adolescent pregnancies, termination of undesired pregnancies, contraception for adolescents, prevention and treatment of sexually transmitted diseases, and other gynecological pathologies. The noncontraceptive benefits of the new-generation 17β estradiol oral contraceptives have been studied in combination with the favorable effects of the progestins as the improvement of acne, the regulation of the menstrual cycle, the prevention of endometrial and ovarian cancers, the prevention of benign ovarian cysts, the management of endometriosis, the severity of pelvic inflammatory diseases, the protection of bone mass, the management of the polycystic ovarian disease, as well as the beneficial effect on the liver function and the lipid profile. Adolescents are usually unaware of the beneficial effects of the oral contraceptives and especially for the effects of the young generation pills. Thus consultation on contraception should include frank explanation on the use and action of the pills as well as for their long-term beneficial effects. On the other hand, the oral contraceptives’ “negative effects” should be considered before treatment. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Creatsas G (1995) Adolescent pregnancy in Europe. Int J Fertil 40(Suppl 2):80–84 Creatsas G (1997) Improving adolescent sexual behaviour: a tool for better fertility outcome and safe motherhood. Int J Gynecol Obstet 58(1):85–92 Creatsas G, Deligeoroglou E (2009) Pediatric, adolescent & young adult gynecology. In: Altchek A (ed) Contraception in adolescence. Wiley, Chichester Creatsas G, Vekemans M, Horejsi J, Uzel R, Lauritzen C, Osler M, Athea N, Toublanc JE, Molnar A, Orley J, Bruni V, Rademakers J, Siegberg R, Widholm O, Stedman Y (1995) Adolescent sexuality in Europe: A multicentric study. Adolesc Pediatr Gynecol 8:59–63 Finer LB, Henslaw SK (2006) Disparities in the rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38:90–96 Alsina JC (2010) After 50 years of ethinylestradiol, another oestrogen in combined in oral contraceptives. Eur J Contracept Reprod Health Care 15(1):1–3 Deligeorogluou E, Creatsas G (2012) Menstrual disorders. Endocr Dev 22:160–170 Kuhl H (1997) Ideal dose of ethinylestradiol. In: Elstein K (ed) Extragenital effects of oral contraceptives. Parthenon Publishing Group, New York, NY, pp 27–38 Hoffmann H, Moore C (1998) Approaches to the replacement of ethinylestradiol by natural 17 beta- estradiol in combined oral contraceptives. Exp Toxicol Pathol 50(4–6):458–464 Krattenmacher R (2000) Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62(1):29–38 Lattakova M, Borovsky M, Payer J, Killinger Z (2009) Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls. Eur J Contracept Reprod Health Care 14(3):207–214 Mansour D, Verhoeven C, Sommer W, Weisberg E, Taneepanichskul S, Melis CB, Sundstrom-Poromaa I, Korver T (2011) Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β- oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 16(6):430–443 Agren UM, Antilla M, Macnpaa-Liukko K, Rantala ML, Rautiainen H, Sommer WF, Mommers E (2011) Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17-b oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care 16(6):458–467 Agren UM, Antilla M, Macnpaa-Liukko K, Rantala ML, Rautiainen H, Sommer WF, Mommers E (2011) Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17-b oestradiol with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 16(6):444–457 American College of Obstetricians and Gynecologists, Women’s Health Care Physicians (2010) Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 115(1):206–218 Creatsas G, Kontopoulou-Griva I, Deligeoroglou E, Tsangaris A, Kallipolitis G, Milingos S, Michalas S (1997) Effects of two combined monophasic and triphasic ethinylestradiol/gestodene oral contraceptives on natural inhibitors and other hemostatic variables. Eur J Contracept Reprod Health Care 2:31–38 Haider Z, D’Souza R (2009) Non-contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol 23:249–262 Westhoff C, Kaunitz A, Korver T, Sommer W, Bahamondes L, Darney P, Verhoeven C (2012) Efficacy, safety and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β – estradiol. Obstet Gynecol 119(5):989 Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2014 Springer International Publishing Switzerland About this chapter Cite this chapter Creatsas, G.K., Creatsas, M. (2014). Noncontraceptive Benefits of 17β-Estradiol COCs During Adolescence. In: Genazzani, A.R., Brincat, M. (eds) Frontiers in Gynecological Endocrinology. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-03494-2_4 Download citation DOI: https://doi.org/10.1007/978-3-319-03494-2_4 Publisher Name: Springer, Cham Print ISBN: 978-3-319-03493-5 Online ISBN: 978-3-319-03494-2 eBook Packages: MedicineMedicine (R0)

- Oral Contraceptive - Pelvic Inflammatory Disease - Ethinyl Estradiol - Combine Oral Contraceptive - Ethinyl Estradiol These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.